The short version of copper tripeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Gly-His-Lys | Three amino acids, histidine in the middle |
| Complex formula | C14H22CuN6O4 | One copper(II) ion per peptide |
| Molar mass (complex) | approx. 402.9 g/mol | Depends on counterion and hydration state |
| Appearance | Blue to blue-violet solid | Colour arises from copper coordination |
| Common synonyms | Copper tripeptide-1, GHK-Cu | Naming varies between disciplines |
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
To avoid the complications involved in using activities, stability constants are determined, where possible, in a medium consisting of a solution of a background electrolyte at high ionic strength, that is, under conditions in which
Furthermore, the reaction conditions can be carefully controlled for desired product distribution, allowing for selective synthesis of desired cage structures. This dynamic character also enables template-directed synthesis, where specific molecular templates can guide the assembly process toward predetermined architectures. Both experimentally and computationally, various synthetic approaches have been developed to control cage formation and optimize yields. The choice of synthetic strategy significantly influences the final cage structure, purity, and scalability of the synthesis. Strategic synthetic approaches range from simple one-pot reactions to sophisticated template-directed methods, each offering distinct advantages.
Metoprolol, sold under the brand names Lopressor and Toprol-XL among others, is a medication used to treat angina, high blood pressure and a number of conditions involving an abnormally fast heart rate. It is also used to prevent further heart problems after myocardial infarction and to prevent headaches in those with migraines. It is a beta blocker, specifically a selective competitive β1 receptor blocker, and is taken by mouth or is given intravenously. Common side effects include trouble sleeping, feeling tired, feeling faint, and abdominal discomfort. Large doses may cause serious toxicity. Risk in pregnancy has not been ruled out. It appears to be safe in breastfeeding. The metabolism of metoprolol can vary widely among patients, often as a result of hepatic impairment or CYP2D6 polymorphism. Metoprolol was first made in 1969, patented in 1970, and approved for medical use in 1978. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the sixth most commonly prescribed medication in the United States, with more than 59 million prescriptions.
Sources: en.wikipedia.org
Neuroscience is the scientific study of the nervous system (the brain, spinal cord, and peripheral nervous system), its functions, and its disorders. It is a multidisciplinary science that combines physiology, anatomy, molecular biology, developmental biology, cytology, psychology, physics, computer science, chemistry, medicine, statistics, and mathematical modeling to understand the fundamental and emergent properties of neurons, glia, and neural circuits. The understanding of the biological basis of learning, memory, behavior, perception, and consciousness has been described by Eric Kandel as the "epic challenge" of the biological sciences. The scope of neuroscience has broadened over time to include different approaches used to study the nervous system at different scales. The techniques used by neuroscientists have expanded enormously, from molecular and cellular studies of individual neurons to imaging of sensory, motor, and cognitive tasks in the brain.
Portal is a 2007 puzzle-platform game developed and published by Valve. It was originally released in a bundle, The Orange Box, for Windows, Xbox 360 and PlayStation 3, and has been ported to other systems, including Mac OS X, Linux, Android (via Nvidia Shield), and Nintendo Switch. Portal is a first person game. It consists primarily of a series of puzzles that must be solved by teleporting the player's character and simple objects using the "Aperture Science Handheld Portal Device", also referred to as the "portal gun", a device that can create portals between locations in the puzzles. The player character, Chell, is challenged and taunted by an artificial intelligence construct named GLaDOS (Genetic Lifeform and Disk Operating System) to complete each puzzle in the Aperture Science Enrichment Center using the portal gun with the promise of receiving cake when all the puzzles are completed. The Source engine's physics system allows kinetic energy to be retained through portals, requiring creative use of portals to maneuver through the test chambers. This gameplay element is based on a similar concept from the game Narbacular Drop; many of the team members from the DigiPen Institute of Technology who worked on Narbacular Drop were hired by Valve for the creation of Portal. Portal was acclaimed as one of the most original games of 2007, despite some criticism for its short duration. It received praise for its originality, unique gameplay, dark story and sense of comedy.
Significant breast development in transgender women begins within two to three months of the start of hormone therapy and continues for up to two years or more. Breast development seems to be better in transgender women who have a higher body mass index. This indicates that weight gain in the early phases of hormone therapy may be beneficial not only for fat distribution, but for breast development. Different estrogens, such as estradiol valerate, conjugated estrogens, and ethinylestradiol, appear to produce equivalent results in terms of breast sizes in transgender women. The sudden discontinuation of estrogen therapy has been associated with onset of galactorrhea (lactation). Breast, nipple, and areolar development varies considerably depending on genetics, nutrition, age of HRT initiation, and many other factors. Development can take a couple years to nearly a decade for some. However, many transgender women report there is often a "stall" in breast growth during transition, or significant breast asymmetry. Transgender women on HRT often experience less breast development than cisgender women (especially if started after young adulthood). For this reason, many seek breast augmentation. Transgender patients opting for breast reduction are rare. Shoulder width and the size of the rib cage also play a role in the perceivable size of the breasts; both are usually larger in transgender women, causing the breasts to appear proportionally smaller.
Sources: en.wikipedia.org
ISBN 978-0-521-89996-3. Tulard, Jean (1984). Napoleon: The Myth of the Saviour. Methuen. ISBN 978-0-416-39510-5. Upshall, Michael, ed. (1993). The Wordsworth Pocket Encyclopedia. Wordsworth Editions. ISBN 978-1-85326-301-9. White, Matthew (2014), Statistics of Wars, Oppressions and Atrocities of the Nineteenth Century, retrieved 3 May 2017. This source references: Bodart, Gaston (1916), Losses of Life in Modern Wars Dumas, Samuel (1923), Losses of Life Caused By War Urlanis, Boris (1971), Wars and Population Payne, Stanley G., A History of Spain and Portugal, vol. 2 Danzer, Arme-Zeitun (in German) Clodfelter, Micheal, Warfare and Armed Conflict: A Statistical Reference to Casualty and Other Figures, 1618–1991 Young, Peter; Lawford, J. P. (2015). Wellington's Masterpiece: The Battle and Campaign of Salamanca. Routledge. ISBN 978-1-317-39728-1.
== Determination of activity == Activity of glutathione peroxidase is measured spectrophotometrically using several methods. A direct assay by linking the peroxidase reaction with glutathione reductase with measurement of the conversion of NADPH to NADP is widely used. The other approach is measuring residual GSH in the reaction with Ellman's reagent. Based on this, several procedures for measuring glutathione peroxidase activity were developed using various hydroperoxides as substrates for reduction, e.g. cumene hydroperoxide, tert-butyl hydroperoxide and hydrogen peroxide. The other methods include the use of CUPRAC reagent with spectrophotometric detection of the reaction product or o-phtalaldehyde as a fluorescent reagent.
== Overdose == Finasteride has been studied in humans at single doses of up to 400 mg and at continuous dosages of up to 80 mg/day for three months, without adverse effects observed. There is no specific recommended antidote for finasteride overdose.
The missing technique that made radar practical was the use of pulses to determine range by measuring the time between the transmission of the signal and reception of the reflected signal. This would allow a single station to measure angle and range simultaneously. In 1924, two researchers at the Naval Research Laboratory in the United States, Merle Tuve and Gregory Briet, decided to recreate Appleton's experiment using timed pulsed signals instead of the changing wavelengths. The application of this technique to a detection system was not lost on those working in the field, and such a system was prototyped by W. A. S. Butement and P. E. Pollard of the British Signals Experimental Establishment (SEE) in 1931. The War Office proved uninterested in the concept and the development remained little known outside SEE.
Sources: en.wikipedia.org
The peptide is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence commonly abbreviated GHK. It binds a single copper(II) ion under typical laboratory conditions. The free peptide and the copper complex are separate chemical species with different properties.
The sequence was identified in human plasma in 1973. Early work examined its presence in blood and its proposed role in tissue repair. The copper-binding property was characterized afterward and became the focus of much later research.
The tripeptide has been measured in human plasma and other biological fluids. Whether it circulates mainly as the copper complex or as the free peptide remains an open question. Natural concentrations are low and difficult to measure reliably.
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.